Is progression of IgA nephropathy conditioned by genes regulating atherosclerotic damage

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3573-3575

  Coppo, Rosanna ^a   Feehally, John ^b  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Adhesion molecules; Genetic factors; IgA nephropathy; Progression

Indexed keywords

ATHEROSCLEROSIS; DISEASE COURSE; GENE CONTROL; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; NOTE; PATHOGENESIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ATHEROSCLEROSIS; DISEASE PROGRESSION; GLOMERULONEPHRITIS, IGA; HUMANS;

EID: 71049168012     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp524     Document Type: Note

References (38)

1. Hsu SI, Ramirez SB, Winn MP et al. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 2000; 57: 1818-1835
2. Lo HS, Wang Z, Hu Y et al. Allelic variations in gene expression is common in the human genome. Genome Res 2003; 13: 1855-1862
3. Gharavi AG, Yan Y, Scolari F et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000; 26: 354-357
4. Bisceglia L, Cerullo G, Forabosco P et al. European IgAN Consortium. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet 2006; 79: 1130-1134
5. Paterson AD, Liu XQ, Wang K et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol 2007; 18: 2408-2415
6. Liu XQ, Paterson AD, He N et al. IL5RA and TNFRSF6B gene variants are associated with sporadic IgA nephropathy. J Am Soc Nephrol 2008; 19: 1025-1033
7. Halldórsson BV, Bafna V, Lippert R et al. Optimal haplotype block-free selection of tagging SNPs for genome-wide association studies Genome Res 2004; 14: 1633-1640
8. Allen AC, Harper SJ, Feehally J. Galactosylation of N-and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995; 100: 470-474
9. LiGS, Zhang H, LvJCet al. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int 2007; 71: 448-453
10. Malycha F, Eggermann T, Hristov M et al. No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrol Dial Transplant 2009; 24: 321-324
11. Suzuki H, Fan R, Zhang Z et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119: 1668-1677
12. Roos A, Rastaldi MP, Calvaresi N et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006; 17: 1724-1734
13. Moura IC, Benhamou M, Launay P et al. The glomerular response to IgA deposition in IgA nephropathy. Semin Nephrol 2008; 28: 88-95
14. Coppo R, Amore A, Gianoglio B et al. Angiotensin II local hyperre-activity in the progression of IgA nephropathy. Am J Kidney Dis 1993; 21: 593-602
15. Yong D, Qing WQ, Hua L et al. Association of angiotensin I-converting enzyme gene insertion/deletion polymorphism and IgA nephropathy: a meta-analysis. Am J Nephrol 2006; 26: 511-518
16. Goto S, Narita I, Saito N et al. A(-20)C polymorphism of the an-giotensinogen gene and progression of IgA nephropathy. Kidney Int 2002; 62: 980-985 (Pubitemid 35316728)
17. Suzuki H, Sakuma Y, Kanesaki Y et al. Close relationship of plas-minogen activator inhibitor-1 4G/5G polymorphism and progression of IgA nephropathy. Clin Nephrol 2004; 62: 173-179
18. Bonnet F, Deprele C, Sassolas A et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720-727
19. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42
20. Nikolopoulos GK, Tsantes AE, Bagos PG et al. Integrin, alpha 2 gene C807T polymorphism and risk of ischemic stroke: a meta-analysis. Thromb Res 2007; 119: 01-10
21. Hillis GS, Roy-Chaudhury P, Duthie LA et al. Expression of beta 1 integrins in IgA nephropathy. Nephrol Dial Transplant 1997; 12: 1137-1142
22. Giancotti FG, Ruoslahti E: Integrin signaling. Science 1999; 285: 1028-1032
23. Peruzzi L, Trusolino L, Amore A et al. Tubulointerstitial responses in the progression of glomerular diseases: albuminuria modulates alpha v beta 5 integrin. Kidney Int 1996; 50: 1310-1320
24. Holder AL, Wolf S, Walshe C et al. Expression of endothelial intercellular adhesion molecule-1 is determined by genotype: effects on efficiency of leukocyte adhesion to human endothelial cells. Hum Immunol 2008; 69: 71-78
25. Jiang H, Klein RM, Niederacher D et al. C/T polymorphism of the intercellular adhesion molecule-1 gene (exon 6, codon 469). A risk factor for coronary heart disease and myocardial infarction. Int J Cardiol 2002; 84: 171-177
26. Tomino Y, Ohmuro H, Kuramoto T et al. Expression of intercellular adhesion molecule-1 and infiltration of lymphocytes in glomeruli of patients with IgA nephropathy. Nephron 1994; 67: 302-307
27. Arrizabalaga P, Sole M, Abellana R et al. Tubular and interstitial expression of ICAM-1 as a marker of renal injury in IgA nephropathy. Am J Nephrol 2003; 23: 121-128
28. Roberts ISD, Cook HT, Troyanov S et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classificationofIgA nephropathy: rationale, clinicopatho-logical correlations, and proposal for classification. Kidney Int 2009; 76: 534-545
29. Cattran D, Coppo R, Cook TH et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: pathology definitions, correlations and reproducibility. Kidney Int 2009; 76: 546-556
30. peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Di al Int 2005; 25: 248-255
31. Marron B, Remon C, Perez-Fontan M et al. Benefits of preserving residual renal function in peritoneal dialysis. Kidney Int Suppl 2008; 73: S42-S51
32. Pecoits-Filho R, Stenvinkel P, Heimburger O et al. Beyond the membrane-the role of new PD solutions in enhancing global bio-compatibility. Kidney Int Suppl 2003; 64: S124-S132
33. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
34. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729
35. Kuypers DR, Vanrenterghem YC. Tailoring immunosuppressive therapy. Nephrol Dial Transplant 2002; 17: 2051-2054
36. Tazza L, Di NA, Bossola M et al. Ageing of patients on chronic dialysis: effects on mortality-A 12-year study. Nephrol Dial Transplant 2008; 24: 940-947
37. Devins GM, Mendelssohn DC, Barre PE et al. Predialysis psychoed-ucational intervention extends survival in CKD: a 20-year follow-up. Am J Kidney Dis 2005; 46: 1088-1098
38. Goldstein M, Yassa T, Dacouris N et al. Multidisciplinary predialysis care and morbidity and mortality of patients on dialysis. Am J Kidney Dis 2004; 44: 706-714